Harpoon Therapeutics, Inc. (NASDAQ:HARP) Receives $4.71 Average PT from Brokerages

Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $4.71.

Several equities analysts have recently commented on HARP shares. Canaccord Genuity Group lowered their price objective on Harpoon Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, April 3rd. HC Wainwright lowered their price target on Harpoon Therapeutics from $7.00 to $4.50 and set a “buy” rating on the stock in a report on Wednesday, March 29th. Finally, 500.com restated a “reiterates” rating on shares of Harpoon Therapeutics in a research note on Monday, May 15th.

Insider Buying and Selling at Harpoon Therapeutics

In other Harpoon Therapeutics news, Director Ronald Hunt bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 23rd. The stock was purchased at an average cost of $1,000.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $10,000,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 13.00% of the stock is currently owned by company insiders.

Institutional Trading of Harpoon Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HARP. Piper Sandler & CO. bought a new stake in Harpoon Therapeutics in the third quarter worth about $563,000. Millennium Management LLC lifted its stake in shares of Harpoon Therapeutics by 3,145.9% during the 2nd quarter. Millennium Management LLC now owns 579,919 shares of the company’s stock worth $1,108,000 after acquiring an additional 562,053 shares during the last quarter. Levin Capital Strategies L.P. purchased a new position in Harpoon Therapeutics during the 4th quarter valued at $239,000. Renaissance Technologies LLC boosted its holdings in Harpoon Therapeutics by 51.6% during the 3rd quarter. Renaissance Technologies LLC now owns 481,041 shares of the company’s stock valued at $467,000 after acquiring an additional 163,680 shares during the period. Finally, BlackRock Inc. grew its position in Harpoon Therapeutics by 5.6% in the 1st quarter. BlackRock Inc. now owns 1,809,686 shares of the company’s stock valued at $8,994,000 after acquiring an additional 95,355 shares during the last quarter. Hedge funds and other institutional investors own 65.52% of the company’s stock.

Harpoon Therapeutics Trading Up 1.8 %

Harpoon Therapeutics stock opened at $0.76 on Friday. Harpoon Therapeutics has a 12-month low of $0.54 and a 12-month high of $3.35. The firm has a market capitalization of $24.52 million, a price-to-earnings ratio of -0.44 and a beta of 1.56. The firm has a 50 day moving average of $0.68 and a 200 day moving average of $0.77.

Harpoon Therapeutics (NASDAQ:HARP – Get Rating) last posted its quarterly earnings results on Monday, March 27th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.08). Harpoon Therapeutics had a negative return on equity of 473.13% and a negative net margin of 169.83%. The firm had revenue of $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. On average, analysts predict that Harpoon Therapeutics will post -1.13 EPS for the current year.

Harpoon Therapeutics Company Profile

(Get Rating)

Harpoon Therapeutics, Inc is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies.